Stock Updates

How has Novo Nordisk A/S:(NYSE:NVO) performed recently?

Novo Nordisk A/S (NYSE: NVO) is a large market cap stock with a market cap of 95574.29. It is in the Drug Manufacturers – Other industry and sector Healthcare, with a current P/E of 21.99, a forward P/E of 19.56 and EPS of 2.16. At a stock price of 47.58 (0.36%) it has a dividend yield of 2.97%.

EPS growth for the last five years have been 22.40%, more recently this last year it has grown by 34.30%. The next year growth is going to be about 6.78% and more long-term 10.60% after five years. EPS growth quarter over quarter is 21.50%. Sales growth for the past five years have been 12.20% and sales growth quarter over quarter is 1.50%.

For performance, Novo Nordisk A/S the past week has seen a gain of 0.62%. For the last month performance for Novo Nordisk A/S is -13.45%. While the last quarter is -12.93% and half year, -4.70%. Finally for the year, performance is -7.75%.

The 52-week high for Novo Nordisk A/S, is at -17.15%, and for the 52-week low it comes to a value of 5.88%. The 20-day simple moving average is -8.50% and -10.72% for the 200-day simple moving average.

Volatility for the week is at 1.09%, and for the month it is 1.28%. Novo Nordisk A/S, has a target price of 57.

In terms of debt, long term debt/equity is 0, and for total debt/equity Novo Nordisk A/S has 0.01. The gross margin is 84.80%, while operating margin is 43.40%, the profit margin is 32.70%. The current ratio is 1.3 and the quick ratio is 0.9.

Insider ownership is at 26.40%, with instituitional ownership at 10.00%. Novo Nordisk A/S has a payout ratio of 45.20%. With the total shares outstanding coming to 2015.91. The shares float is 1356.68, with the float short at 0.16%, with short ratio coming to 1.06.

In terms of returns, the return on assets see Novo Nordisk A/S, get 41.50%, with its returns on investment at 85.00%. Return on equity is 84.90%. So will the investors see the target price of 57, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Peter Clarke

Leave a Comment